PMID- 28323985
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20180515
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 6
DP  - 2017 Jun 1
TI  - Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine 
      Tumors in MEN1.
PG  - 1926-1933
LID - 10.1210/jc.2016-3865 [doi]
AB  - CONTEXT: Patients with multiple endocrine neoplasia type 1 (MEN1) are at high 
      risk of malignant pancreatic neuroendocrine tumors (pNETs). Structural imaging is 
      typically used to screen for pNETs but is suboptimal for stratifying malignant 
      potential. OBJECTIVE: To determine the utility of fluorodeoxyglucose (18F) 
      positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting 
      the malignant potential of pNETs in MEN1. DESIGN: Retrospective observational 
      study. SETTING: Tertiary referral hospital. PATIENTS: Forty-nine adult patients 
      with MEN1 carrying a common MEN1 mutation who underwent 18F-FDG PET/CT for MEN1 
      surveillance between 1 January 2010 and 30 September 2016. INTERVENTIONS: 
      Structural and functional imaging (magnetic resonance imaging, CT, 
      ultrasonography, and 18F-FDG PET/CT) and surgical histopathology. MAIN OUTCOME 
      MEASURES: pNET size, behavior, and histopathology. RESULTS: Twenty-five (51.0%) 
      of 49 patients studied had pancreatic lesions on structural imaging. Five (25%) 
      of these had 18F-FDG-PET-avid lesions. In addition, two had solitary FDG-avid 
      liver lesions, and one a pancreatic focus without structural correlate. Eight 
      patients with pNETs underwent surgery (three FDG-avid lesions and five nonavid 
      pNETs). The Ki-67 index was >/=5% in FDG-avid pNETs and <2% in nonavid pNETs. 
      Overall, six of the eight (75%) patients with FDG-avid hepatopancreatic lesions 
      harbored aggressive or metastatic NETs compared with one of 41 patients (2.4%) 
      without hepatopancreatic FDG avidity [P < 0.001; sensitivity; 85.7% (95% 
      confidence interval [CI], 48.7% to 99.3%); specificity, 95.2% (95% CI, 84.2% to 
      99.2%)]. CONCLUSION: 18F-FDG PET/CT is an effective screening modality in MEN1 
      for identifying pNETs of increased malignant potential. Surgical resection is 
      recommended for FDG-avid pNETs.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Kornaczewski Jackson, Elena R
AU  - Kornaczewski Jackson ER
AD  - Department of Diabetes and Endocrinology, Royal Hobart Hospital, Hobart, Tasmania 
      7000, Australia.
FAU - Pointon, Owen P
AU  - Pointon OP
AD  - Department of Nuclear Medicine, Royal Hobart Hospital, Hobart, Tasmania 7000, 
      Australia.
FAU - Bohmer, Robert
AU  - Bohmer R
AD  - Department of Surgery, Royal Hobart Hospital, Hobart, Tasmania 7000, Australia.
FAU - Burgess, John R
AU  - Burgess JR
AD  - Department of Diabetes and Endocrinology, Royal Hobart Hospital, Hobart, Tasmania 
      7000, Australia.
AD  - School of Medicine, University of Tasmania, Hobart, Tasmania 7000, Australia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Liver Neoplasms/*diagnostic imaging/secondary
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*complications
MH  - Neuroendocrine Tumors/*diagnostic imaging/etiology/secondary/surgery
MH  - Pancreatic Neoplasms/*diagnostic imaging/etiology/pathology/surgery
MH  - Positron Emission Tomography Computed Tomography
MH  - Radiopharmaceuticals
MH  - Retrospective Studies
MH  - Tumor Burden
MH  - Ultrasonography
EDAT- 2017/03/23 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/03/22 06:00
PHST- 2016/12/06 00:00 [received]
PHST- 2017/02/28 00:00 [accepted]
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
PHST- 2017/03/22 06:00 [entrez]
AID - 3063339 [pii]
AID - 10.1210/jc.2016-3865 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Jun 1;102(6):1926-1933. doi: 10.1210/jc.2016-3865.